Thalidomide
- Generic Name
- Thalidomide
- Brand Names
- Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C13H10N2O4
- CAS Number
- 50-35-1
- Unique Ingredient Identifier
- 4Z8R6ORS6L
- Background
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
- Indication
Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).
- Associated Conditions
- Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
- Associated Therapies
- -
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193544
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2019-02-05
- Target Recruit Count
- 47
- Registration Number
- NCT00179881
- Locations
- 🇺🇸
Children's Hospitals and Clinics, Saint Paul, Minnesota, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States
🇺🇸Washington University Medical Center, Saint Louis, Missouri, United States
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00182663
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-04-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 32
- Registration Number
- NCT00165230
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2011-07-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165451
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma
- Conditions
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2007-12-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 37
- Registration Number
- NCT00165217
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
- Conditions
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2010-06-22
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 19
- Registration Number
- NCT00162760
- Locations
- 🇺🇸
Johns Hopkins School of Medicine, Baltimore, Maryland, United States
Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2005-09-12
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT00155272
- Locations
- 🇨🇳
NTUH, Taipei, Taiwan
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 25
- Registration Number
- NCT00151281
- Locations
- 🇺🇸
Weill Medical College of Cornell University, New York, New York, United States
Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-02
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- Steven P. Treon, MD, PhD
- Target Recruit Count
- 25
- Registration Number
- NCT00142116
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.